Premium
Three‐Year Follow‐up of Lanthanum Carbonate Therapy in Hemodialysis Patients
Author(s) -
Takeuchi Kazuhisa,
Matsuda Etsuko,
Sekino Makoto,
Hasegawa Yukiko,
Kamo Yoshie,
Kikuchi Natsue,
Sekino Hiroshi
Publication year - 2013
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/1744-9987.12045
Subject(s) - lanthanum carbonate , hyperphosphatemia , medicine , phosphate binder , sevelamer , dose , hemodialysis , gastroenterology , vitamin d and neurology , dialysis , incidence (geometry) , concomitant , ergocalciferol , calcium , endocrinology , cholecalciferol , physics , optics
For 3 years following the start of lanthanum carbonate therapy, effects on other pharmaceutical treatment with sevelamer hydrochloride ( SH ), calcium carbonate ( CC ), and vitamin D , and those on clinical condition were examined. Dialysis patients with hyperphosphatemia (89 cases; average age 55.2 years; dialysis history of 10 years; 50 male and 39 female), who agreed to start lanthanum carbonate ( LC ) administration, were observed for a mean period of 32.6 ± 6.2 months. Mean daily dosages of CC and SH before starting LC were 2.68 g and 0.73 g; mean daily dosage amounts of LC , CC , and SH at the time of final evaluation were 0.87 g, 2.30 g, and 0.99 g, respectively. After the application of LC , serum phosphate as well as serum calcium controls were significantly improved, and the amounts of active vitamin D agents applied was significantly increased. In conclusion, LC is useful in managing serum phosphorus levels (P levels), and little incidence of hypercalcemia suggests favorable concomitant use with active vitamin D agents in LC therapy.